Citing the minutes from recent meetings with the FDA, Zosano Pharma (NASDAQ:ZSAN) remains confident that it has compiled all necessary data to support a marketing application for migraine patch Qtrypa (zolmitriptan), expected to be filed next month.
Shares up 9% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.